Sox17-flox Mouse
一般名
Sox17-flox
製品ID
S-CKO-05182
背景情報
C57BL/6JCya
系統ID
CKOCMP-20671-Sox17-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Sox17-flox Mouse(カタログ番号S-CKO-05182)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Sox17-flox
系統ID
CKOCMP-20671-Sox17-B6J-VA
遺伝子名
製品ID
S-CKO-05182
遺伝子別名
--
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 1
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000027035
NCBIトランスクリプトID
NM_011441
ターゲット領域
Exon 5
有効領域の大きさ
~2.7 kb
遺伝子研究の概要
SOX17, SRY-box transcription factor 17, is a crucial transcription factor. It directs the specification and development of the primitive endoderm, primitive germ cells, and definitive endoderm, and is involved in the cardiovascular system and several endoderm-derived organs. It participates in pathways like Wnt/β-catenin and Notch signaling during development [5,7].
In cancer, in vitro-engineered colon cancer organoids with Apc-null, KrasG12D and Trp53-null (AKP) mutations showed strong up-regulation of SOX17 in vivo. SOX17 loss did not impact AKP organoid propagation in vitro but significantly reduced AKP tumour persistence in vivo. SOX17-null tumours had IFNγ-producing effector-like CD8+ T cell infiltrates, unlike the immune-suppressive microenvironment in wild-type counterparts. SOX17 suppresses tumour cells' ability to sense and respond to IFNγ, and engages a fetal intestinal programme to drive differentiation away from LGR5+ tumour cells, producing immune-evasive LGR5-tumour cells with lower MHC-I expression, enabling immune evasion in early colorectal adenomas and cancers [1].
In pulmonary hypertension, SOX17 expression was downregulated in patients' lungs and pulmonary endothelial cells. Tie2Cre-mediated Sox17 knockdown and EC-specific Sox17 deletion in mice induced spontaneous mild pulmonary hypertension, and loss of endothelial Sox17 exacerbated hypoxia-induced pulmonary hypertension. SOX17 deficiency led to endothelial dysfunctions, and E2F1 signaling mediated these effects, which could be attenuated by E2F1 inhibitor [2]. Also, Sox17 expression was reduced in PAH tissues. Chronic hypoxic pulmonary hypertension was exacerbated in Sox17EC-/-mice and attenuated in Sox17Tg mice. SOX17 promoted oxidative phosphorylation and mitochondrial function in pulmonary artery endothelial cells, in part via inhibition of HIF2α. 16α-hydroxyestrone (16αOHE) mediated PAH development via down-regulation of SOX17 [3]. Common PAH risk variants upstream of the SOX17 promoter reduced endothelial SOX17 expression through differential binding of HOXA5 and ROR-α, resulting in disturbed endothelial cell function and PAH [4]. Endothelial knockdown of SOX17 accelerated, while overexpression attenuated, SU5416/hypoxia-induced PH in mice. SOX17-associated exosomes blocked HPAECs' proliferation, apoptosis, and inflammation, preventing pulmonary arterial remodeling and PH [6].
In conclusion, SOX17 is vital for embryonic development and tissue homeostasis. Gene-knockout and conditional-knockout mouse models have revealed its role in promoting immune evasion in early colorectal cancers and maintaining endothelial function to prevent pulmonary hypertension. Understanding SOX17's functions provides insights into disease mechanisms and potential therapeutic targets for these diseases.
References:
1. Goto, Norihiro, Westcott, Peter M K, Goto, Saori, Agudo, Judith, Yilmaz, Ömer H. 2024. SOX17 enables immune evasion of early colorectal adenomas and cancers. In Nature, 627, 636-645. doi:10.1038/s41586-024-07135-3. https://pubmed.ncbi.nlm.nih.gov/38418875/
2. Yi, Dan, Liu, Bin, Ding, Hongxu, Fallon, Michael B, Dai, Zhiyu. 2023. E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension. In Hypertension (Dallas, Tex. : 1979), 80, 2357-2371. doi:10.1161/HYPERTENSIONAHA.123.21241. https://pubmed.ncbi.nlm.nih.gov/37737027/
3. Sangam, Shreya, Sun, Xutong, Schwantes-An, Tae-Hwi, Black, Stephen M, Desai, Ankit A. . SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics. In American journal of respiratory and critical care medicine, 207, 1055-1069. doi:10.1164/rccm.202203-0450OC. https://pubmed.ncbi.nlm.nih.gov/36913491/
4. Walters, Rachel, Vasilaki, Eleni, Aman, Jurjan, Zhao, Lan, Rhodes, Christopher J. 2023. SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. In Circulation, 147, 1606-1621. doi:10.1161/CIRCULATIONAHA.122.061940. https://pubmed.ncbi.nlm.nih.gov/37066790/
5. Tan, Daisylyn Senna, Holzner, Markus, Weng, Mingxi, Srivastava, Yogesh, Jauch, Ralf. 2019. SOX17 in cellular reprogramming and cancer. In Seminars in cancer biology, 67, 65-73. doi:10.1016/j.semcancer.2019.08.008. https://pubmed.ncbi.nlm.nih.gov/31419525/
6. Zou, Xiaozhou, Liu, Ting, Huang, Zhongjie, Zhang, Yiwen, Huang, Ping. 2023. SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10, e2206139. doi:10.1002/advs.202206139. https://pubmed.ncbi.nlm.nih.gov/36919784/
7. Zhu, Na, Welch, Carrie L, Wang, Jiayao, Shen, Yufeng, Chung, Wendy K. 2018. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. In Genome medicine, 10, 56. doi:10.1186/s13073-018-0566-x. https://pubmed.ncbi.nlm.nih.gov/30029678/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
